News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neurosearch A/S (NEUR.CO) Says to Cut Workforce by a Fifth, To Concentrate Resources Behind Main Product Huntington's Disease Drug Huntexil


1/11/2011 6:45:18 AM

Reuters -- Danish biopharma company Neurosearch (NEUR.CO) is to cut costs and 20 percent of its workforce to concentrate resources behind its main product under development, Huntington's disease drug Huntexil.

Read at Reuters
Read at Bloomberg
Read at PharmaLive

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES